Connect with us
Prague Gaming & TECH Summit 2024

Artificial Intelligence

Growing Demand for Clinical Diagnosis Applications Offers Expansion Avenues in Multiplex Detection Immunoassays Market, Opines TMR

Published

on

 

The increased number of chronic and infectious health disorders across major parts of the globe is expected to generate high sales opportunities in the global multiplex detection immunoassays market during the forecast period from 2020 to 2030.

Protein-based techniques, biosensor-based techniques, and nucleic acid-based techniques are used in the multiplex detection immunoassays.

A new study by Transparency Market Research (TMR) estimates that the global multiplex detection immunoassays market will grow from US$ 1.5 Bn in 2019 to over 3.65 Bn by 2030.

Strong expertise with attention to detail makes our market research reports stand apart, Request a Report Sample here – https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=64341

Multiplex Detection Immunoassays Market: Key Findings

  • Surging Demand for Point of Care Diagnostic Devices Fuels Market Growth

Point of care diagnostic devices help to perform rapid initial screenings in diverse non-laboratory settings. With the growing focus of healthcare professionals toward offering high level of convenience to patients, the trend of “near-patients tests” is increasing. This factor is translating into increased product sales from the market.

  • Researchers Focus on Development of Multiplex Immunoassay for Rapid Detection of Human Coronaviruses

Researchers and scientists across the globe are concentrated on the development of multiplex serologic assays, which will allow for rapid detection and examination of known human coronaviruses. These researches are projected to drive the growth of the global multiplex detection immunoassays market in the upcoming years.

Request for Analysis of COVID-19 Impact on Multiplex Detection Immunoassays Market – https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=64341

Multiplex Detection Immunoassays Market: Growth Boosters

  • Growing emphasis on R&D activities, increasing need for early and rapid detection of antibiotic remainders for environmental and food protection, and rising number of chronic and infectious diseases are projected to fuel the expansion of global multiplex detection immunoassays market during the forecast period 2020–2030
  • Researchers today are focused on the development of novel diagnostic tests and tools for prevention and diagnosis of varied diseases. This factor is projected to help in market growth. Moreover, the notable growth of the number of various surgical procedures across the globe is anticipated to boost the sales avenues in the market in the near future.
  • Clinical research organizations, pharmaceutical & biopharmaceutical companies, academic & research institutes, diagnostic centers, and food & beverages industry are some of the key end users of the multiplex detection immunoassays
  • Diagnostic laboratories and hospitals today are facing many critical issues such as presence of strict rules and regulations, growing operational costs, declining reimbursements and revenues, absence of skilled workforce, and high level of competition in the industry. However, increased need for preventive treatment and drug monitoring, and growth in the older population around the world are some of the key factors creating lucrative avenues for the healthcare industry, which, in turn, is estimated to drive demand opportunities in the market.
  • The multiplex detection immunoassays market is likely to show promising growth opportunities in the Asia Pacific region. This growth can be ascribed to many factors such as increased instances of chronic diseases, improved healthcare infrastructure, rise in number of cardiovascular diseases, growth in awareness about importance of routine checkups and diagnosis, and considerable surge in product approval activities in the region. Moreover, several leading market players are focused on their expansion in developing regions. Thus, they are engaged in mergers and acquisitions activities.

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough, ask for custom research here – https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=64341

Multiplex Detection Immunoassays Market: Key Players

The report performs profiling of key players working in the multiplex detection immunoassays market. Thus, the research document provides all important information such as the company overview, product portfolio, financial overview, recent developments, and business strategies of each player operating in the market.

The list of key players in the multiplex detection immunoassays market includes the following:

  • QIAGEN
  • Hoffmann-La Roche Ltd
  • Microsynth AG
  • Merck KGaA
  • Thermo Fisher Scientific
  • Bio-Rad Laboratories
  • Becton
  • Luminex Corporation
  • Dickinson and Company

Purchase Premium Research Report on Multiplex Detection Immunoassays Market – https://www.transparencymarketresearch.com/checkout.php?rep_id=64341&ltype=S

Global Multiplex Detection Immunoassays Market: Segmentation

Multiplex Detection Immunoassays Market, by Assay Type

  • Planar Assay
  • Blends Protein Arrays (Multiplexed ELISA)
  • Antibody Arrays
  • Bead-based Assay
  • Magnetic Bead-based
  • Non-magnetic Bead-based

Multiplex Detection Immunoassays Market, by Technique

  • Nucleic Acid-based Techniques
  • Protein-based Techniques
  • Biosensor-based Techniques

Multiplex Detection Immunoassays Market, by Application

  • Disease Testing
  • Infectious Disease Testing
  • Autoimmune Disease Testing
  • Other Diseases Testing
  • Food Contamination Testing
  • Research & Development
  • Veterinary Disease Testing

Multiplex Detection Immunoassays Market, by End User

  • Pharmaceutical & Biopharmaceutical Companies
  • Clinical Research Organizations
  • Food & Beverages Industry
  • Academic & Research Institutes
  • Diagnostic Centers
  • Others

Multiplex Detection Immunoassays Market, by Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

Modernization of healthcare in terms of both infrastructure and services have pushed the healthcare industry to new heights, Stay Updated with Latest Healthcare Industry Research Reports by Transparency Market Research:

Life Science Instrumentation Market: With the rising incidence of various infectious diseases such as COVID-19, the government bodies of several countries all across the globe have increased funds toward research activities to find out the medications to control this health condition. This factor is working in favor of the global life science instrumentation market.

Chemiluminescence Immunoassay Analyzers Market: According to the report, the global chemiluminescence immunoassay (CLIA) analyzers market was valued at US$ 5.04 Bn in 2018 and is anticipated to expand at a CAGR of 6.3% from 2019 to 2027, growing demand for international accreditations and result comparability using high throughput automated immunoassays is likely to drive the market.

Enteric Disease Testing Market: According to the report, the global enteric disease testing market was valued at US$ 3.8 Bn in 2018 and is anticipated to expand at a CAGR of 3.3% from 2019 to 2027, high morbidity and rapid spread of enteric bacterial infections is projected to drive the global market during the forecast period

Artificial Intelligence

XtalPi Unveils XtalGazer: A Comprehensive AI-Driven Polymorph Selection Platform

Published

on

xtalpi-unveils-xtalgazer:-a-comprehensive-ai-driven-polymorph-selection-platform

CAMBRIDGE, Mass., March 28, 2024 /PRNewswire/ — XtalPi Inc., a leading global technology company in integrating artificial intelligence (AI) and robotics to advance the discovery of groundbreaking medicine and innovative materials, announced today the launch of its proprietary comprehensive solid form discovery and selection platform, XtalGazer. This advanced platform aims to significantly improve the polymorph selection process for the pharmaceutical industry by integrating AI- and automation-powered experimental and computational approaches.

XtalGazer provides a total solution for delivering high-quality polymorph screening and selection methods to expedite drug development and mitigate risks. It represents a paradigm shift in solid-state research, moving from the traditional trial-and-error approach to a data-driven, design-led methodology. The platform provides an expansive suite of foundational tools to accelerate polymorph discovery, characterization, and selection process, empowering pharmaceutical companies to conduct thorough research with less active pharmaceutical ingredient (API) in shorter development cycles.
A key component of XtalGazer is XtalCSP, a crystal structure prediction platform to perform global searches of crystal structures for target molecules and the other optional components in the corresponding searching space, offering a deep insight into possible stable forms. Furthermore, crystallization strategy recommendations will provide AI-backed experimental design to help avoid human bias. XtalGazer also utilizes MicroED to rapidly elucidate crystal structures from powder samples, reducing the need for growing single crystals.
XtalPi’s launch of XtalGazer marks another significant step in the company’s ongoing exploration of solid-state research. From crystal structure prediction platforms being one of the first products to launch at XtalPi, to today’s comprehensive polymorph selection platform, XtalPi will keep fulfilling its promise to solving challenging problems in this space. XtalPi will continue to deliver faster, more accurate, and more comprehensive approaches to building an ecosystem for the R&D process in solid-state, pre-formulation and crystallization.
For more information about XtalPi, please visit www.xtalpi.com.
About XtalPi:
XtalPi is an innovative technology company powered by artificial intelligence (AI) and robotics. Founded in 2015 on the MIT campus, XtalPi is dedicated to driving intelligent and digital transformation in the life science and new materials industries. With tightly interwoven quantum physics, AI, cloud computing, and large-scale clusters of robotic workstations, XtalPi offers a range of technology solutions, services, and products to accelerate and empower innovation for biopharmaceutical and new materials companies worldwide.
Media Contact: Vivienne [email protected]
Logo – https://mma.prnewswire.com/media/632519/XtalPi_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/xtalpi-unveils-xtalgazer-a-comprehensive-ai-driven-polymorph-selection-platform-302102794.html

Continue Reading

Artificial Intelligence

ICIS and Base Oil News Announce Partnership to Enhance Market Insights

Published

on

icis-and-base-oil-news-announce-partnership-to-enhance-market-insights

LONDON, March 28, 2024 /PRNewswire/ — ICIS, a global source of commodity intelligence, is pleased to announce a strategic partnership with Base Oil News, a premier news outlet founded by industry expert Iain Pocock that provides in-depth coverage of the base oils and lubricants market. This collaboration marks a significant milestone in the dissemination and exchange of critical market data and insights.

With more than two decades of journalism experience at Bloomberg, Reuters, and Argus Media, Iain Pocock brings unparalleled expertise to this partnership. His deep understanding of illiquid energy markets makes him a credible and influential figure in the industry. Since November 2023, Iain has been working closely with ICIS to share and exchange valuable data and insights, enhancing the services both platforms offer to the base oils and lubricants market.
Through the collaboration, Iain integrates ICIS’ extensive content and data resources in Base Oil News market coverage. In return, he contributes market insights to ICIS News, including expert and exclusive analysis of supply and demand dynamics, price margins, and other critical market drivers. This exchange ensures that subscribers of both ICIS and Base Oil News have access to the most comprehensive, timely, and accurate market information, empowering them to make informed decisions.
“It’s a very exciting partnership – where we leverage each other’s strengths and provide actionable insights to our customers,” said Iain Pocock, Founder of Base Oil News. “The market is the winner.”
“As ICIS is already the world’s most trusted pricing benchmark for base oils, this collaboration with Iain Pocock and Base Oil News provides an even stronger and deeper service to our customers,” said Stephen Burns, Editorial Director at ICIS. “Iain’s expertise and extensive industry connections are invaluable, and we have established a fruitful partnership that benefits the market at large.”
For the latest insights from Iain Pocock on ICIS News, visit ICIS News.  
About ICIS
ICIS – Independent Commodity Intelligence Services – helps businesses through seamlessly delivering data and analytics, across the chemical, fertilizer and energy markets. A trusted source and benchmark for price information and insight across key commodities markets worldwide. Our independent, transparent market intelligence informs thousands of quality decisions every day, taking the pressure out of negotiations and giving customers space for more innovative thinking, through published datasets including price assessments, price forecasts, supply and demand fundamentals and more.
Over 150 years of shaping the world by connecting markets to optimise the world’s valuable resources. With a global team of more than 600 experts, ICIS has employees based in London, New York, Houston, Karlsruhe, Milan, Mumbai, Singapore, Guangzhou, Beijing, Shanghai, Dubai, Sao Paulo, Seoul, Tokyo and Perth.
ICIS is part of RELX, a FTSE15 company with a market cap of £64bn and an employee base of over 30,000 experts across 40 countries.
About RELX
RELX is a global provider of information and analytics for professional and business customers across industries. The Group serves customers in more than 180 countries and has offices in about 40 countries. It employs approximately 30,000 people of whom almost half are in North America. RELX PLC is a London listed holding company which owns 52.9% of RELX Group. RELX NV is an Amsterdam listed holding company which owns 47.1% of RELX Group. The shares are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX and RENX. Total market capitalisation is approximately £64bn | €75bn | $81bn.
Logo: https://mma.prnewswire.com/media/619935/4277787/ICIS_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/icis-and-base-oil-news-announce-partnership-to-enhance-market-insights-302102782.html

Continue Reading

Artificial Intelligence

Trianz Welcomes Israel Abraham as Vice President of Services for Extrica.ai – The Data to AI Platform

Published

on

trianz-welcomes-israel-abraham-as-vice-president-of-services-for-extrica.ai-–-the-data-to-ai-platform

SANTA CLARA, Calif., March 28, 2024 /PRNewswire/ — Digital transformation technology & services company Trianz is pleased to announce the appointment of Israel Abraham as Vice President of Extrica Platform Services.

Trianz has embarked on a transformative journey, redefining its value proposition with an ‘IP Led’ model, with a commitment to deliver the fastest time to value, lowest human dependence, and highest ROI. Central to this approach are our hyper-automated platforms, Concierto.Cloud, Extrica.AI, and Pulse, driving industry-leading transformations in cloud, data and analytics, AI, and the digital workplace.
Israel Abraham is a very well-known pioneer and industry leader in AI, data management, and analytics systems, with over three decades of experience. He joins as the services leader for Extrica- the Trianz Data to AI platform, which productizes data, provides data a face and purpose, and accelerates time to insights and AI by 50% or more. In the role of Extrica Services leader, Israel will lead the shaping, visioning, and delivery of Extrica.ai based enterprise wide datamesh, BI, and AI solutions for customers worldwide.
“We are thrilled to welcome Israel Abraham to the Trianz family,” said Sri Manchala, CEO of Trianz and author of Crossing the Digital Faultline. “He is a leader in modernization as well as conceptualization of data platforms anew. Israel’s prior background in the industry with financial services and insurance giants underscores our commitment to securing top-tier talent that brings real-world experiences and needs to our technology platforms. As we continue to broaden our footprint in the digital transformation space, Israel’s visionary leadership and practical experience will serve as the cornerstone in accelerating insights and AI to deliver transformative value to our clients.”
Having played pivotal roles in highly reputed and large organizations such as Liberty Mutual Insurance, MassMutual, Safeco, and CNA Insurance, Israel has garnered recognition as a seasoned leader in big data and AI cloud implementations. His accolades include the prestigious 2014 Ventana Research IT Innovation Award, the 2009 Informatica MDM Innovation Award, and three filed Data Engineering patents in the last four years.
“Trianz has been at the forefront of digital innovation, and Extrica.ai is a paradigm shifting data to AI platform that completely changes how analytics and AI are delivered- much faster, taking business ahead of change. I am excited to scale the adoption of the Extrica platform, which has attracted attention from giants across the industry and hyperscalers,” said Israel Abraham. “I look forward to engaging with customers, bringing my own experiences, and collaborating with the talented team at Trianz to further enhance the capabilities of the Extrica Platform Services to transform data & AI strategies, execution, and outcomes for customers.”
About Trianz
Trianz is a leading-edge technology platforms and services company that accelerates digital transformations at Fortune 100 and emerging companies worldwide in data & analytics, digital experiences, cloud infrastructure, and security. Our ‘IP Led Transformations’ approach, informed by insights from a recent global study spanning 20+ industries and 5000+ companies, addresses challenges posed by the rapid pace of AI-driven transformation, digital talent scarcity, and economic uncertainty. Our IP and platforms, including Concierto, Extrica, and Pulse, revolutionize cloud adoption, data analytics, and AI insights, empowering organizations to navigate the complexities of digital transformation seamlessly.
Founded in California and with an organization of over 2,000 associates across the United States and India, Trianz is a Premier Partner of AWS, consistently rated #1 by clients for value delivery over the past five years. Trianz has been ranked as one of the best Consulting Firms by Forbes and has been certified as a Great Place to Work for three years in a row. To learn more about Trianz, email [email protected] or visit www.trianz.com.
Watch Trianz CEO Sri Manchala’s insightful interview with Bloomberg on Partner | Crossing The Digital Faultline & Leading Towards Transformative Success – YouTube and delve deeper into his book Crossing the Digital Faultline at Crossing the Digital Faultline | Trianz.
Trianz Media [email protected] +1-408-387-5800
Logo: https://mma.prnewswire.com/media/626944/1199800/Trianz_Logo.jpg
 

View original content:https://www.prnewswire.co.uk/news-releases/trianz-welcomes-israel-abraham-as-vice-president-of-services-for-extricaai–the-data-to-ai-platform-302102589.html

Continue Reading
Advertisement

Latest News

Trending